

EUROPEAN HEART HOUSE

Pulmonary Hypertension: Future expectations and annual G6 meeting

Friday 19 – Saturday 20 October 2012

Pulmonary Circulation
and Right Ventricular
Function
ESC Working Group



Course Directors:

N. Galiè (IT), G. Simonneau (FR)

Faculty:

D. Badesch (USA), M. Beghetti (CH), A. El-Gazayerly (NL), G. Fischer (AT), A. Ghofrani (DE), S. Gibbs (UK), W. Gin-Sing (UK), D. Ivy (USA), N. Kim (USA), J. Newman (USA), W. Seeger (DE), O. Sitbon (FR), A. Torbicki (PL), R. Tuder (USA), J.L. Vachieri (BE), A. Vonk Noordegraaf (NL)

Scientific Programme

Thursday 18 October

Welcome dinner

Friday 19 October

08:30 – 08:50 Registration

Session 1: N. Galiè - G. Simonneau

08:50 - 09:00 Welcome and Introduction - G. Simonneau

09:00 - 09:30 Pathology – R. Tuder

09:30 - 10:00 Pathobiology – R. Tuder

10:00 - 10:30 Genetics/Genomics – J. Newman

10:30 - 11:00 Coffee Break

11:00 - 11:30 Definitions and Classifications - G. Simonneau

11:30 - 12:00 Pathophysiology - A.Vonk Noordegraaf

12:00 - 13:00 Lunch

Session 2: S. Gibbs, O. Sitbon

13:00 – 13:30 Epidemiology and registries – O. Sitbon

13:30 – 14:00 Diagnosis and Prognosis – D. Badesch

14:00 – 14:30 Therapy – Standard of care - N. Galiè

14:30 – 15:00 Discussion

15:00 – 15:30 Coffee break

Session 3 JL Vachieri, M. Beghetti

15:30 – 16:00 Therapy – Goals – O. Sitbon

16:00 – 16:30 New Design and New Therapies – A. Ghofrani

16:30 – 17:00 CTEPH – N. Kim

17:00 – 17:30 PH due to Left Heart Disease and Chronic Lung

Disease – W. Seeger

17:30 – 18:00 Pediatric PH – D. Ivy

Saturday 20 October

Session 4 – G 6 Meeting: A Torbicki, G.Fischer

09:00 – 09:30 Expectations from Patients – G. Fischer

09:30 – 10:00 Expectation from Nurses – W. Gin-Sing

10:00 – 10:30 Coffee Break

10:30 – 10:50 The expectations of the Regulatory Agencies

A. El Gazayerly

10:50 – 11:10 The expectations of the Industry

M. Ianosev

11:10– 11:30 The pediatric-sildenafil study and the FDA decisions D.Ivy

11:30 – 12:00 Discussion

Session 5: N. Galiè - G. Simonneau

12:00–12:45 Roundtable discussion with invited representatives of healthcare providers, industry, regulatory agencies and policy makers (M. Alison (Bayer), L. Varanese (Eli-Lilly), M. Ianosev (GSK), S. Teal (Pfizer), A.Maresta (Actelion), A. El Gazayerly

12:45 – 13:00 Summary of the meeting and perspectives
N. Galiè

13:00 Lunch & Departure